{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:05:04Z","timestamp":1789005904906,"version":"build-2803163510"},"reference-count":15,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["US Cardiol"],"abstract":"<jats:p>Amyloidosis is caused by extracellular deposition of amyloid protein in various organs and tissues. Light-chain amyloidosis is the most common systemic amyloidosis, whereas transthyretin amyloid cardiomyopathy is emerging as the underdiagnosed variant, especially in the elderly. Cardiac MRI and technetium-99m-pyrophosphate scintigraphy are specific non-invasive modalities that have simplified the diagnostic accuracy of cardiac amyloidosis. Identifying the type of amyloidosis is of paramount importance, given the differences in management protocols. Increased left-ventricular wall thickness and diastolic dysfunction are the most easily detectable manifestations of cardiac amyloidosis. Atrial involvement is early in both light-chain and transthyretin amyloidosis and is associated with high risk of arrhythmias and thromboembolic events. We report a case of wild-type transthyretin amyloid cardiomyopathy with predominant involvement of the right atrium and patchy involvement of the right and left ventricles.<\/jats:p>","DOI":"10.15420\/usc.2024.30","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:48:17Z","timestamp":1743504497000},"source":"Crossref","is-referenced-by-count":1,"title":["A Right-atrial Variant of Wild-type Transthyretin Cardiac Amyloidosis"],"prefix":"10.15420","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-9272","authenticated-orcid":false,"given":"Narra","family":"Lavanya","sequence":"first","affiliation":[{"name":"Department of Cardiology, KIMS Hospitals, Kondapur, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0520-3566","authenticated-orcid":false,"given":"Abraham","family":"Oomman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Apollo Main Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Hawkins PN. Systemic amyloidosis. Curr Opin Pharmacol 2006;6:214\u201320. https:\/\/doi.org\/10.1016\/j.coph.2005.10.005; PMID:\u00a016483845.","DOI":"10.1016\/j.coph.2005.10.005"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387:2641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X; PMID:\u00a026719234.","DOI":"10.1016\/s0140-6736(15)01274-x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ruberg FL,\u00a0Grogan M,\u00a0Hanna M,\u00a0et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003; PMID:\u00a031171094.","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 2020;13:1368\u201383. https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.015; PMID:\u00a031607664.","DOI":"10.1016\/j.jcmg.2019.07.015"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Bandera F, Martone R, Chacko L, et al. Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. JACC Cardiovasc Imaging 2022;15:17\u201329. https:\/\/doi.org\/10.1016\/j.jcmg.2021.06.022; PMID:\u00a034419399.","DOI":"10.1016\/j.jcmg.2021.06.022"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Vergaro G, Aimo A, Rapezzi C, et al. Atrial amyloidosis: mechanisms and clinical manifestations. Eur J Heart Fail 2022;24:2019\u201328. https:\/\/doi.org\/10.1002\/ejhf.2650; PMID:\u00a035920110.","DOI":"10.1002\/ejhf.2650"},{"key":"ref6","unstructured":"Merlo M, Pagura L, Porcari A, et al. Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 2022;24:1377\u201386. https:\/\/doi.org\/10.1002\/ejhf.2504; PMID: 35417089."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin- related versus light-chain cardiac amyloidosis. Circulation 2014;129:1840\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.006242; PMID:\u00a024563469.","DOI":"10.1161\/circulationaha.113.006242"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 2016;16:129. https:\/\/doi.org\/10.1186\/s12872-016-0311-6; PMID:\u00a027267362.","DOI":"10.1186\/s12872-016-0311-6"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Non-biopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612; PMID:\u00a027143678.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Kaye GC, Butler MG, D\u2019Ardenne AJ, et al. Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J 1986;56:317\u201320. https:\/\/doi.org\/10.1136\/hrt.56.4.317; PMID:\u00a02945573.","DOI":"10.1136\/hrt.56.4.317"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Rfcken Ch, Peters B, Juenemann G, et al. Atrial amyloidosis. An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091\u20137. https:\/\/doi.org\/10.1161\/01.cir.0000034511.06350.df; PMID:\u00a012379579.","DOI":"10.1161\/01.cir.0000034511.06350.df"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Brett W, et al. Regional variation in technetium pyrophosphate uptake in transthyretin\u00a0cardiac amyloidosis and\u00a0impact on\u00a0mortality. J Am Coll Cardiol Img 2018;11:234\u201342.","DOI":"10.1016\/j.jcmg.2017.06.020"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Pan D, Bouligand J, Guiochon-Mantel A, Adams D. FAP in India: a first genetically proven case. Orphanet J Rare Dis 2015;10(Suppl 1):P20. https:\/\/DOI.ORG\/10.1186\/1750-1172-10-S1-P20.","DOI":"10.1186\/1750-1172-10-s1-p20"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Sharma V, Sharma P, Singh M, et al. An unusual case of hereditary transthyretin-related amyloidosis and ulcerative colitis in a young Indian girl. JGH Open 2020;4:289\u201391. https:\/\/doi.org\/10.1002\/jgh3.12206; PMID:\u00a032280781.","DOI":"10.1002\/jgh3.12206"}],"container-title":["US Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T10:48:43Z","timestamp":1743504523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.uscjournal.com\/articleindex\/usc.2024.30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":15,"URL":"https:\/\/doi.org\/10.15420\/usc.2024.30","relation":{},"ISSN":["1758-390X","1758-3896"],"issn-type":[{"value":"1758-390X","type":"electronic"},{"value":"1758-3896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"e08"}}